Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central anxious technique, conolidine modulates alternate molecular targets. A Science Improvements study uncovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://saeeds097uxz9.wikiadvocate.com/user